Parkman Healthcare Partners LLC Arcus Biosciences, Inc. Transaction History

Parkman Healthcare Partners LLC

$770 Million
Q1 2025

A detailed history of Parkman Healthcare Partners LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 1,215,629 shares of RCUS stock, worth $10.6 Million. This represents 1.24% of its overall portfolio holdings.

Number of Shares

1,215,629

Previous 1,273,789 4.57%

Holding current value

$10.6 Million

Previous $19 Million 49.69%

% of portfolio

1.24%

Previous 2.76%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.85 - $15.24 $456,556 - $886,358	-58,160 Reduced 4.57%	1,215,629 $9.54 Million
Q4 2024 Feb 14, 2025	BUY	$14.28 - $18.44 $3.54 Million - $4.57 Million	248,035 Added 24.18%	1,273,789 $19 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $8.35 Million - $11 Million	610,219 Added 146.85%	1,025,754 $15.7 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $2.27 Million - $2.88 Million	155,615 Added 59.87%	415,535 $6.33 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $181,756 - $247,326	12,256 Added 4.95%	259,920 $4.91 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $571,513 - $835,354	42,555 Added 20.75%	247,664 $4.73 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $1.5 Million - $2 Million	85,060 Added 70.85%	205,109 $3.68 Million
Q2 2023 Aug 11, 2023	BUY	$16.97 - $22.03 $289,542 - $375,875	17,062 Added 16.57%	120,049 $2.44 Million
Q1 2023 May 12, 2023	BUY	$15.96 - $23.15 $247,810 - $359,450	15,527 Added 17.75%	102,987 $1.88 Million
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $993,549 - $1.8 Million	-50,434 Reduced 36.57%	87,460 $1.81 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $774,023 - $1 Million	-33,320 Reduced 19.46%	137,894 $3.61 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $67,076 - $146,882	3,893 Added 2.33%	171,214 $4.34 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $1.45 Million - $2.1 Million	50,222 Added 42.89%	167,321 $5.28 Million
Q4 2021 Feb 11, 2022	SELL	$31.38 - $48.47 $3.75 Million - $5.79 Million	-119,538 Reduced 50.52%	117,099 $4.74 Million
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $269,300 - $376,800	-10,000 Reduced 4.05%	236,637 $8.25 Million
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $1.58 Million - $2.48 Million	-69,245 Reduced 21.92%	246,637 $6.77 Million
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $2.2 Million - $3.48 Million	84,124 Added 36.3%	315,882 $8.87 Million
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $55,760 - $106,140	-3,280 Reduced 1.4%	231,758 $6.02 Million
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $1.29 Million - $1.91 Million	75,038 Added 46.9%	235,038 $4.03 Million
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $2.24 Million - $5.85 Million	160,000 New	160,000 $3.96 Million

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

63.2M

Call Options Held

116K

Put Options Held

116K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $629M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.

Account

Parkman Healthcare Partners LLC Arcus Biosciences, Inc. Transaction History